epidoxorubicin + docetaxel + cyclophosphamide + methotrexate + fluorouracil

A multi-agent chemotherapy combination consisting of **epidoxorubicin**, **docetaxel**, **cyclophosphamide**, **methotrexate**, and **fluorouracil**. Each component is a well-established cytotoxic agent with distinct mechanisms, commonly used in the treatment of various cancers, especially solid tumors like breast cancer. - **Epidoxorubicin** is an anthracycline antibiotic, acting as a topoisomerase II inhibitor, intercalating DNA, and producing free radicals leading to DNA damage. - **Docetaxel** is a taxane that promotes and stabilizes microtubule assembly, inhibiting cell division. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, resulting in apoptosis. - **Methotrexate** is an antimetabolite and antifolate, inhibiting dihydrofolate reductase and thus DNA synthesis. - **Fluorouracil (5-FU)** is another antimetabolite, a pyrimidine analog, which inhibits thymidylate synthase disrupting DNA and RNA synthesis[1][2][3][6]. Together, these mechanisms provide broad antineoplastic effects, and such combinations are typically used in curative or adjuvant settings for malignancies such as breast cancer, gastrointestinal cancers, and other solid tumors.